Kavar Capital Partners Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Kavar Capital Partners Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-175	Closed	-$55K	–	378
2019 Q2	$55K	Buy	+175	New	+$58.3K	0.02%	222
2018 Q3	–	Sell	-175	Closed	-$60K	–	315
2018 Q2	$60K	Hold	175	–	–	0.03%	171
2018 Q1	$60K	Buy	+175	New	+$60.9K	0.03%	170
2016 Q1	–	Sell	-175	Closed	-$95K	–	323
2015 Q4	$95K	Sell	175 -50	-22%	-$27.1K	0.06%	133
2015 Q3	$104K	Hold	225	–	–	0.07%	129
2015 Q2	$114K	Buy	+225	New	+$110K	0.08%	137
2014 Q2	–	Sell	-4	Closed	-$1K	–	365
2014 Q1	$1K	Buy	+4	New	+$1.23K	﹤0.01%	467

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Kavar Capital Partners Group's REGN Position: Q3 2019 in Review

Kavar Capital Partners Group sold out of Regeneron Pharmaceuticals (REGN) in Q3 2019, closing a stake of 175 shares — an estimated $55K sold.

Kavar Capital Partners Group first reported a position in REGN in Q1 2014 and held it in 7 quarters. The position peaked at $114K in Q2 2015. 633 funds tracked by Wall St. Rank hold REGN as of Q3 2019.

Kavar Capital Partners Group reported no remaining Regeneron Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Kavar Capital Partners Group sold 175 Regeneron Pharmaceuticals shares in Q3 2019, an estimated $55K.
Kavar Capital Partners Group first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Kavar Capital Partners Group's Regeneron Pharmaceuticals position peaked at $114K in Q2 2015.
633 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2019.

Based on Kavar Capital Partners Group's 13F filing for Q3 2019, filed 12 Nov 2019.